by PEPID Newsroom | Jan 2, 2019 | Alerts
The injection Ultomirus (ravulizumab) has been approved for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Ultomiris is a long-acting complement inhibitor that prevents hemolysis. Richard Pazdur, M.D., director of the FDA’s Oncology...
by PEPID Newsroom | Dec 27, 2018 | Alerts
FDA approved ProAir digihaler by Asthmapolis, the first app-connected digital inhaler. The ProAir Digihaler has built-in sensors to detect when the device is used and the strength of the user’s inhalation. This data is then sent via Bluetooth to its mobile app...
by PEPID Newsroom | Dec 17, 2018 | Alerts
There’s a new drug for people suffering from Chronic Idiopathic Constipation(CIC) headed to the market in 2019. The US FDA has approved Motegrity with the active ingredient Prucalopride for the treatment of CIC presented by Shire Dev LLC. Motegrity is a...
by PEPID Newsroom | Dec 11, 2018 | Alerts
The Lancet reports the first successful live birth from a uterus transplant. In September 2016, a 32-year-old woman in Brazil with congenital uterine absence, or Mayer-Rokitansky-Küster-Hauser [MRKH] syndrome, underwent a successful uterine transplantation from a...
by PEPID Newsroom | Dec 10, 2018 | Alerts
FDA clears mobile medical app reSET-O to help opioid use disorder patients stay in recovery programs. This new method of treatment is a prescription cognitive behavioral therapy to be used in conjunction with treatment that includes buprenorphine and contingency...
by PEPID Newsroom | Dec 3, 2018 | Press & Media
Phoenix, AZ, USA, December 3, 2018 — PEPID, LLC, trusted developer of top clinical decision support solutions, is eager to announce the latest additions to its ever-growing drug and clinical database. Beginning December 2018, subscribers on any platform can reference...
by Anna Tan | Nov 28, 2018 | Uncategorized
Healthcare reform and improvement has entered exciting times. Medical R&D and health informatics (HIT) are growing at a rapid rate, offering better options to a more curious and proactive generation of consumers. More regulatory bodies and forward-thinking...
by PEPID Newsroom | Nov 20, 2018 | Alerts
The FDA approved Aemcolo (rifamycin) yesterday for the treatment of travelers’ diarrhea. Aemcolo is an antibacterial drug to treat noninvasive strains of Escherichia coli (E. coli) not complicated by fever or blood in the stool. The FDA estimates 10-40% of travelers...
by Anna Tan | Nov 19, 2018 | Pharmacy
Today’s healthcare industry is a race between technology, policy, and support, with the endpoint for all of them being a more patient-centered approach. Technological advancements have made precision medicine possible, resulting in an explosion of data and inquiries...
by Anna Tan | Nov 14, 2018 | Pharmacy
Moving Forward with Proper PGx Expectations 2,5Pharmacogenomic (PGx) testing and PGx-based treatments may be all the rage in precision medicine today, but more genetic and pharmacology experts – especially in the areas of cardiology, pain management, and psychiatry –...
